Similar articles for PMID: 15277417

Year	Number of Results
1969	1
1988	1
1999	1
2000	2
2001	4
2002	5
2003	7
2004	6
2005	3
2006	1
2007	1
2008	3
2009	10
2010	6
2011	8
2012	13
2013	12
2014	13
2015	17
2016	18
2017	11
2018	11
2019	25
2020	29
2021	8

1

The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes.

Harder H, Nielsen L, Tu DT, Astrup A. Harder H, et al. Diabetes Care. 2004 Aug;27(8):1915-21. doi: 10.2337/diacare.27.8.1915. Diabetes Care. 2004. PMID: 15277417 Clinical Trial.

2

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.

Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR; NN2211-1310 International Study Group. Madsbad S, et al. Diabetes Care. 2004 Jun;27(6):1335-42. doi: 10.2337/diacare.27.6.1335. Diabetes Care. 2004. PMID: 15161785 Clinical Trial.

3

Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults.

van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH. van Can J, et al. Int J Obes (Lond). 2014 Jun;38(6):784-93. doi: 10.1038/ijo.2013.162. Epub 2013 Sep 3. Int J Obes (Lond). 2014. PMID: 23999198 Free PMC article. Clinical Trial.

4

Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes.

Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O; Liraglutide Dose-Response Study Group. Feinglos MN, et al. Diabet Med. 2005 Aug;22(8):1016-23. doi: 10.1111/j.1464-5491.2005.01567.x. Diabet Med. 2005. PMID: 16026367 Clinical Trial.

5

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.

Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agersø H, Veldhuis J, Pørksen N, Schmitz O. Juhl CB, et al. Diabetes. 2002 Feb;51(2):424-9. doi: 10.2337/diabetes.51.2.424. Diabetes. 2002. PMID: 11812750 Free article. Clinical Trial.

6

Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.

Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M. Larsen PJ, et al. Diabetes. 2001 Nov;50(11):2530-9. doi: 10.2337/diabetes.50.11.2530. Diabetes. 2001. PMID: 11679431 Free article.

7

The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose.

Chang AM, Jakobsen G, Sturis J, Smith MJ, Bloem CJ, An B, Galecki A, Halter JB. Chang AM, et al. Diabetes. 2003 Jul;52(7):1786-91. doi: 10.2337/diabetes.52.7.1786. Diabetes. 2003. PMID: 12829647 Free article. Clinical Trial.

8

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O. Degn KB, et al. Diabetes. 2004 May;53(5):1187-94. doi: 10.2337/diabetes.53.5.1187. Diabetes. 2004. PMID: 15111485 Free article. Clinical Trial.

9

The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.

Flint A, Kapitza C, Hindsberger C, Zdravkovic M. Flint A, et al. Adv Ther. 2011 Mar;28(3):213-26. doi: 10.1007/s12325-010-0110-x. Epub 2011 Feb 17. Adv Ther. 2011. PMID: 21340616 Clinical Trial.

10

Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes.

Kaku K, Rasmussen MF, Clauson P, Seino Y. Kaku K, et al. Diabetes Obes Metab. 2010 Apr;12(4):341-7. doi: 10.1111/j.1463-1326.2009.01194.x. Diabetes Obes Metab. 2010. PMID: 20380655 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed